bismuth subsalicylate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4257	14882-18-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: bismuth subsalicylate bismogenol bismuth oxysalicylate	bismuth subsalicylate is the active ingredient of Pepto-Bismol and in Kaopectate; used to treat nausea, heartburn, indigestion, upset stomach, diarrhea and other temporary discomforts of the stomach; used with Azoles and other drugs to treat Helicobacter Molecular weight: 362.09 Formula: C7H5BiO4 CLOGP: 0.34 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 55.76 ALOGS: -0.78 ROTB: 0 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

bismuth subsalicylate
bismogenol
bismuth oxysalicylate

bismuth subsalicylate is the active ingredient of Pepto-Bismol and in Kaopectate; used to treat nausea, heartburn, indigestion, upset stomach, diarrhea and other temporary discomforts of the stomach; used with Azoles and other drugs to treat Helicobacter

Molecular weight: 362.09
Formula: C7H5BiO4
CLOGP: 0.34
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 55.76
ALOGS: -0.78
ROTB: 0

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Aug. 15, 1996	FDA	PROMETHEUS LABS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Chronic kidney disease	112.36	22.08	53	3400	45345	63440224
Diarrhoea	70.70	22.08	133	3320	715233	62770336
Cholecystitis chronic	52.00	22.08	20	3433	10341	63475228
End stage renal disease	37.49	22.08	14	3439	6679	63478890
Renal injury	29.55	22.08	13	3440	9426	63476143
Cholelithiasis	24.93	22.08	20	3433	43905	63441664
Eyelid pain	23.14	22.08	5	3448	327	63485242

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood phosphorus increased	102.79	27.35	33	2464	7688	34946746
Appendicolith	99.29	27.35	33	2464	8568	34945866
Chronic kidney disease	92.17	27.35	49	2448	41161	34913273
Appendicitis	85.27	27.35	34	2463	14773	34939661
Ventricular fibrillation	70.94	27.35	34	2463	22920	34931514
Stress	67.55	27.35	36	2461	30311	34924123
Cardiogenic shock	66.16	27.35	34	2463	26584	34927850
Dry mouth	64.94	27.35	35	2462	30130	34924304
Abdominal distension	57.08	27.35	41	2456	58451	34895983
Ascites	53.28	27.35	36	2461	46535	34907899
Myasthenia gravis	50.84	27.35	19	2478	6921	34947513
Blood uric acid increased	48.17	27.35	20	2477	9604	34944830
Hyponatraemia	40.74	27.35	39	2458	82652	34871782
Multiple organ dysfunction syndrome	37.50	27.35	36	2461	76530	34877904
Blood cholesterol increased	36.43	27.35	21	2476	20522	34933912
End stage renal disease	36.36	27.35	16	2481	8845	34945589
Analgesic therapy	34.63	27.35	9	2488	989	34953445
Sleep disorder therapy	34.41	27.35	9	2488	1014	34953420
Drug therapy	33.44	27.35	9	2488	1132	34953302
Vomiting	32.59	27.35	61	2436	247560	34706874
Hyperphosphataemia	31.95	27.35	12	2485	4425	34950009
Intentional product misuse	31.36	27.35	26	2471	45585	34908849
Abdominal pain	28.95	27.35	46	2451	163572	34790862
Nausea	27.75	27.35	69	2428	339839	34614595

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Chronic kidney disease	128.88	21.26	69	4984	66085	79673250
Appendicolith	103.25	21.26	33	5020	8518	79730817
Blood phosphorus increased	97.08	21.26	33	5020	10314	79729021
Appendicitis	77.94	21.26	34	5019	20760	79718575
Ventricular fibrillation	64.07	21.26	34	5019	31892	79707443
Cardiogenic shock	58.01	21.26	35	5018	41879	79697456
Blood uric acid increased	47.32	21.26	21	5032	13339	79725996
Vomiting	47.18	21.26	119	4934	665709	79073626
Abdominal distension	46.48	21.26	47	5006	119603	79619732
End stage renal disease	45.84	21.26	20	5033	12200	79727135
Ascites	45.61	21.26	38	5015	75524	79663811
Myasthenia gravis	45.56	21.26	19	5034	10380	79728955
Dry mouth	44.50	21.26	40	5013	87979	79651356
Stress	43.89	21.26	38	5015	79574	79659761
Cholecystitis chronic	43.07	21.26	18	5035	9888	79729447
Diarrhoea	42.53	21.26	137	4916	880352	78858983
Abdominal pain	37.88	21.26	79	4974	389490	79349845
Nausea	37.55	21.26	139	4914	957057	78782278
Analgesic therapy	35.60	21.26	9	5044	1000	79738335
Sleep disorder therapy	35.46	21.26	9	5044	1015	79738320
Drug therapy	34.04	21.26	9	5044	1192	79738143
Multiple organ dysfunction syndrome	30.77	21.26	38	5015	120208	79619127
Hyperphosphataemia	29.11	21.26	12	5041	6364	79732971
Intentional product misuse	27.50	21.26	32	5021	95133	79644202
Nephrogenic anaemia	23.61	21.26	9	5044	3893	79735442
Iron deficiency	23.22	21.26	12	5041	10642	79728693
Renal injury	23.06	21.26	14	5039	16913	79722422
Hyponatraemia	22.02	21.26	40	5013	177808	79561527
Eyelid pain	22.00	21.26	5	5048	353	79738982

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA CS	M0002611	Bismuth
MeSH PA	D000930	Antidiarrheals
MeSH PA	D005765	Gastrointestinal Agents
FDA EPC	N0000180183	Bismuth

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Diarrhea	indication	62315008
Indigestion	indication	162031009
Duodenal Ulcer due to H. Pylori	indication
Traveler's diarrhea	off-label use	11840006
Helicobacter pylori-associated gastritis	off-label use	708164002
Helicobacter Pylori Gastritis	off-label use
Alcoholism	contraindication	7200002
Lowered convulsive threshold	contraindication	19260006
Alcohol intoxication	contraindication	25702006
Hepatic failure	contraindication	59927004
Blood coagulation disorder	contraindication	64779008	DOID:1247
Diabetes mellitus	contraindication	73211009	DOID:9351
Disorder of brain	contraindication	81308009	DOID:936
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Seizure disorder	contraindication	128613002
Non-infective meningitis	contraindication	230155003
Disease of liver	contraindication	235856003	DOID:409
Pregnancy, function	contraindication	289908002
Peripheral nerve disease	contraindication	302226006
Neutropenic disorder	contraindication	303011007	DOID:1227
Pseudomembranous enterocolitis	contraindication	397683000
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Cyclooxygenase	Enzyme	P23219 P35354	PGH1_HUMAN PGH2_HUMAN	INHIBITOR				CHEMBL	CHEMBL

External reference:

ID	Source
4018971	VUID
N0000147252	NUI
D00728	KEGG_DRUG
4018971	VANDF
C0053792	UMLSCUI
CHEBI:261649	CHEBI
CHEMBL1120	ChEMBL_ID
DB01294	DRUGBANK_ID
C015715	MESH_SUPPLEMENTAL_RECORD_UI
62TEY51RR1	UNII
16682734	PUBCHEM_CID
19478	RXNORM
4290	MMSL
d01026	MMSL
001159	NDDF
409307004	SNOMEDCT_US
82075003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
good sense stomach relief	HUMAN OTC DRUG LABEL	1	0113-0469	TABLET, CHEWABLE	262 mg	ORAL	OTC monograph final	16 sections
good sense stomach relief	HUMAN OTC DRUG LABEL	1	0113-0469	TABLET, CHEWABLE	262 mg	ORAL	OTC monograph final	16 sections
basic care stomach relief	HUMAN OTC DRUG LABEL	1	0113-7469	TABLET, CHEWABLE	262 mg	ORAL	OTC monograph final	16 sections
basic care stomach relief	HUMAN OTC DRUG LABEL	1	0113-7469	TABLET, CHEWABLE	262 mg	ORAL	OTC monograph final	16 sections
Stomach Relief	HUMAN OTC DRUG LABEL	1	0121-0910	LIQUID	525 mg	ORAL	OTC monograph final	16 sections
Stomach Relief	HUMAN OTC DRUG LABEL	1	0121-0910	LIQUID	525 mg	ORAL	OTC monograph final	16 sections
Stomach Relief	HUMAN OTC DRUG LABEL	1	0121-0910	LIQUID	525 mg	ORAL	OTC monograph final	16 sections
Stomach Relief	HUMAN OTC DRUG LABEL	1	0121-0910	LIQUID	525 mg	ORAL	OTC monograph final	16 sections
Pink Bismuth	HUMAN OTC DRUG LABEL	1	0121-4803	SUSPENSION	262 mg	ORAL	OTC monograph final	17 sections
Percy Medicine	HUMAN OTC DRUG LABEL	1	0322-2222	LIQUID	1050 mg	ORAL	OTC monograph final	8 sections
Percy Medicine	HUMAN OTC DRUG LABEL	1	0322-2222	LIQUID	1050 mg	ORAL	OTC monograph final	8 sections
Soothe	HUMAN OTC DRUG LABEL	1	0363-0025	LIQUID	525 mg	ORAL	OTC MONOGRAPH FINAL	16 sections
Soothe	HUMAN OTC DRUG LABEL	1	0363-0025	LIQUID	525 mg	ORAL	OTC MONOGRAPH FINAL	16 sections
Soothe	HUMAN OTC DRUG LABEL	1	0363-0073	LIQUID	525 mg	ORAL	OTC MONOGRAPH FINAL	16 sections
Soothe	HUMAN OTC DRUG LABEL	1	0363-0073	LIQUID	525 mg	ORAL	OTC MONOGRAPH FINAL	16 sections
Soothe	HUMAN OTC DRUG LABEL	1	0363-0073	LIQUID	525 mg	ORAL	OTC MONOGRAPH FINAL	16 sections
Soothe	HUMAN OTC DRUG LABEL	1	0363-0073	LIQUID	525 mg	ORAL	OTC MONOGRAPH FINAL	16 sections
Soothe	HUMAN OTC DRUG LABEL	1	0363-0319	TABLET, CHEWABLE	262 mg	ORAL	OTC MONOGRAPH FINAL	16 sections
Soothe	HUMAN OTC DRUG LABEL	1	0363-0319	TABLET, CHEWABLE	262 mg	ORAL	OTC MONOGRAPH FINAL	16 sections
Soothe	HUMAN OTC DRUG LABEL	1	0363-0346	TABLET	262 mg	ORAL	OTC monograph final	16 sections
Soothe	HUMAN OTC DRUG LABEL	1	0363-0346	TABLET	262 mg	ORAL	OTC monograph final	16 sections
SootheMaximum Strength	HUMAN OTC DRUG LABEL	1	0363-0371	LIQUID	1050 mg	ORAL	OTC MONOGRAPH FINAL	16 sections
SootheMaximum Strength	HUMAN OTC DRUG LABEL	1	0363-0371	LIQUID	1050 mg	ORAL	OTC MONOGRAPH FINAL	16 sections
Soothe	HUMAN OTC DRUG LABEL	1	0363-0736	LIQUID	525 mg	ORAL	OTC monograph final	16 sections
Soothe	HUMAN OTC DRUG LABEL	1	0363-0736	LIQUID	525 mg	ORAL	OTC monograph final	16 sections
Ultra Strength digestive relief	HUMAN OTC DRUG LABEL	1	0363-1302	TABLET	525 mg	ORAL	OTC monograph final	17 sections
Soothe	HUMAN OTC DRUG LABEL	1	0363-7240	LIQUID	525 mg	ORAL	OTC monograph final	16 sections
Soothe	HUMAN OTC DRUG LABEL	1	0363-7240	LIQUID	525 mg	ORAL	OTC monograph final	16 sections
SootheUltra Strength	HUMAN OTC DRUG LABEL	1	0363-7370	LIQUID	525 mg	ORAL	OTC monograph final	16 sections
SootheUltra Strength	HUMAN OTC DRUG LABEL	1	0363-7370	LIQUID	525 mg	ORAL	OTC monograph final	16 sections